Stocks Health care GTBP

NASDAQ · Health care

GT Biopharma, Inc. (GTBP)

It posted a net loss of $4.8M. At June 30, 2026 it held $5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What GT Biopharma, Inc. does

GT Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GTBP.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Dividends

It paid out $229K in cash dividends.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What GT Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 25, 2026
   Other event 8-K
2. September 21, 2026
   Material agreement 8-K
3. September 15, 2026
   Passive stake (5% or more) SCHEDULE 13G
4. September 15, 2026
   Material agreement 8-K
5. September 3, 2026
   Shareholder rights changed 8-K
6. August 14, 2026
   Shareholder vote results 8-K
7. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.12 versus -$10.92.
8. July 2, 2026
   Proxy statement DEF 14A
9. June 18, 2026
   Preliminary proxy statement PRE 14A
10. June 12, 2026
    Bylaws or fiscal year changed 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 8, 2025. Insider transactions on SEC

Who owns GTBP

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Bristol Capital, LLC 4.76% (June 2, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GTBP

What does GT Biopharma, Inc. do?

GT Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GTBP.

Is GT Biopharma, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $4.8M.

When did GT Biopharma, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 25, 2026.

Similar companies

Compare GTBP with

Compare GTBP with any company

Follow GTBP

Get an email when GT Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow GTBP: get an email when it files

Where the numbers come from

Financial figures are the values GT Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.